BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, Wu K. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer. 2018;17:129. [PMID: 30139382 DOI: 10.1186/s12943-018-0864-3] [Cited by in Crossref: 197] [Cited by in F6Publishing: 208] [Article Influence: 49.3] [Reference Citation Analysis]
Number Citing Articles
1 Bai X, Yi M, Dong B, Zheng X, Wu K. The global, regional, and national burden of kidney cancer and attributable risk factor analysis from 1990 to 2017. Exp Hematol Oncol 2020;9:27. [PMID: 33005476 DOI: 10.1186/s40164-020-00181-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Yi M, Qin S, Zhao W, Yu S, Chu Q, Wu K. The role of neoantigen in immune checkpoint blockade therapy. Exp Hematol Oncol 2018;7:28. [PMID: 30473928 DOI: 10.1186/s40164-018-0120-y] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 12.8] [Reference Citation Analysis]
3 Wang J, Peng W, Jiang M, Wu L. [Research Progress of Anti-angiogenic Agents Combined with Immunotherapy 
in Patients with Advanced Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2021;24:196-203. [PMID: 33819970 DOI: 10.3779/j.issn.1009-3419.2021.101.05] [Reference Citation Analysis]
4 Zhou WY, Zhang MM, Liu C, Kang Y, Wang JO, Yang XH. Long noncoding RNA LINC00473 drives the progression of pancreatic cancer via upregulating programmed death-ligand 1 by sponging microRNA-195-5p. J Cell Physiol 2019;234:23176-89. [PMID: 31206665 DOI: 10.1002/jcp.28884] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 13.0] [Reference Citation Analysis]
5 Alkassis M, Kourie HR, Sarkis J, Nemr E. Predictive biomarkers in bladder cancer. Biomark Med 2021;15:241-6. [PMID: 33625249 DOI: 10.2217/bmm-2020-0575] [Reference Citation Analysis]
6 Gou M, Qu T, Wang Z, Yan H, Si Y, Zhang Y, Dai G. Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer. J Immunol Res 2021;2021:2549295. [PMID: 34993252 DOI: 10.1155/2021/2549295] [Reference Citation Analysis]
7 García-Aranda M, Redondo M. Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy. Int J Mol Sci 2019;20:E2296. [PMID: 31075880 DOI: 10.3390/ijms20092296] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
8 Wang Y, Shang K, Zhang N, Zhao J, Cao B. Tumor-Associated Macrophage-Derived Exosomes Promote the Progression of Gastric Cancer by Regulating the P38MAPK Signaling Pathway and the Immune Checkpoint PD-L1. Cancer Biother Radiopharm 2021. [PMID: 34698510 DOI: 10.1089/cbr.2021.0218] [Reference Citation Analysis]
9 Wang Y, Duan M, Peng Z, Fan R, He Y, Zhang H, Xiong W, Jiang W. Advances of DNA Damage Repair-Related Drugs and Combination With Immunotherapy in Tumor Treatment. Front Immunol 2022;13:854730. [PMID: 35281059 DOI: 10.3389/fimmu.2022.854730] [Reference Citation Analysis]
10 Wang D, Gong L, Li Z, Chen H, Xu M, Rong R, Zhang Y, Zhu Q. Antifibrotic effect of Gancao Ganjiang decoction is mediated by PD-1 / TGF-β1 / IL-17A pathway in bleomycin-induced idiopathic pulmonary fibrosis. J Ethnopharmacol 2021;281:114522. [PMID: 34391863 DOI: 10.1016/j.jep.2021.114522] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Lian Y, Duffy KJ, Yang J. STING Activation and its Application in Immuno-Oncology. CTMC 2019;19:2205-27. [DOI: 10.2174/1568026619666191010155903] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
12 Chaurasiya S, Yang A, Kang S, Lu J, Kim SI, Park AK, Sivanandam V, Zhang Z, Woo Y, Warner SG, Fong Y. Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model. Oncoimmunology 2020;9:1729300. [PMID: 32158622 DOI: 10.1080/2162402X.2020.1729300] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
13 Niedziałkowski P, Bojko M, Ryl J, Wcisło A, Spodzieja M, Magiera-Mularz K, Guzik K, Dubin G, Holak TA, Ossowski T, Rodziewicz-Motowidło S. Ultrasensitive electrochemical determination of the cancer biomarker protein sPD-L1 based on a BMS-8-modified gold electrode. Bioelectrochemistry 2021;139:107742. [PMID: 33517203 DOI: 10.1016/j.bioelechem.2021.107742] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Scheinberg T, Lomax A, Tattersall M, Thomas D, McCowage G, Sullivan M, Karim R, Luk PP, Mahar A, Bonar F, Bhadri VA. PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma. Cancer Rep (Hoboken) 2021;4:e1327. [PMID: 33314769 DOI: 10.1002/cnr2.1327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Arfè A, Fell G, Alexander B, Awad MM, Rodig SJ, Trippa L, Schoenfeld JD. Meta-Analysis of PD-L1 Expression As a Predictor of Survival After Checkpoint Blockade. JCO Precision Oncology 2020. [DOI: 10.1200/po.20.00150] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Lin T, Zhang Y, Lin Z, Peng L. Roles of HMGBs in Prognosis and Immunotherapy: A Pan-Cancer Analysis. Front Genet 2021;12:764245. [PMID: 34777483 DOI: 10.3389/fgene.2021.764245] [Reference Citation Analysis]
17 Wang Y, Zhang H, He YW. The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy. Front Immunol 2019;10:1574. [PMID: 31379815 DOI: 10.3389/fimmu.2019.01574] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
18 Yang X, Ma L, Zhang X, Huang L, Wei J. Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia. Exp Hematol Oncol 2022;11:11. [PMID: 35236415 DOI: 10.1186/s40164-022-00263-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
19 Yi M, Li A, Zhou L, Chu Q, Luo S, Wu K. Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma. Cancer Immunol Immunother 2021;70:1705-19. [PMID: 33386920 DOI: 10.1007/s00262-020-02817-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
20 Song BN, Kim SK, Mun JY, Choi YD, Leem SH, Chu IS. Identification of an immunotherapy-responsive molecular subtype of bladder cancer. EBioMedicine. 2019;50:238-245. [PMID: 31735557 DOI: 10.1016/j.ebiom.2019.10.058] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 9.7] [Reference Citation Analysis]
21 Onuma AE, Zhang H, Huang H, Williams TM, Noonan A, Tsung A. Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. Gene Expr 2020;20:53-65. [PMID: 32340652 DOI: 10.3727/105221620X15880179864121] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
22 Carbone ML, Madonna G, Capone A, Bove M, Mastroeni S, Levati L, Capone M, Ascierto PA, De Galitiis F, D'Atri S, Fortes C, Volpe E, Failla CM. Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients. Sci Rep 2022;12:5448. [PMID: 35361879 DOI: 10.1038/s41598-022-09373-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Halbert B, Einstein DJ. Hot or Not: Tumor Mutational Burden (TMB) as a Biomarker of Immunotherapy Response in Genitourinary Cancers. Urology 2021;147:119-26. [PMID: 33137348 DOI: 10.1016/j.urology.2020.10.030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Schonfeld M, Zhao J, Komatz A, Weinman SA, Tikhanovich I. The polymorphism rs975484 in the protein arginine methyltransferase 1 gene modulates expression of immune checkpoint genes in hepatocellular carcinoma. J Biol Chem 2020;295:7126-37. [PMID: 32245889 DOI: 10.1074/jbc.RA120.013401] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Felip E, Moreno V, Morgensztern D, Curigliano G, Rutkowski P, Trigo JM, Calvo A, Kowalski D, Cortinovis D, Plummer R, Maio M, Ascierto PA, Vladimirov VI, Cervantes A, Zudaire E, Hazra A, T'jollyn H, Bandyopadhyay N, Greger JG, Attiyeh E, Xie H, Calvo E. First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Cancer Chemother Pharmacol 2022. [PMID: 35298698 DOI: 10.1007/s00280-022-04414-6] [Reference Citation Analysis]
26 Chen P, Gao Y, Ouyang S, Wei L, Zhou M, You H, Wang Y. A Prognostic Model Based on Immune-Related Long Non-Coding RNAs for Patients With Cervical Cancer. Front Pharmacol 2020;11:585255. [PMID: 33328990 DOI: 10.3389/fphar.2020.585255] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
27 Joseph SA, Taglialatela A, Leuzzi G, Huang JW, Cuella-Martin R, Ciccia A. Time for remodeling: SNF2-family DNA translocases in replication fork metabolism and human disease. DNA Repair (Amst) 2020;95:102943. [PMID: 32971328 DOI: 10.1016/j.dnarep.2020.102943] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
28 Qiao PP, Tian KS, Han LT, Ma B, Shen CK, Zhao RY, Zhang Y, Wei WJ, Chen XP. Correlation of mismatch repair deficiency with clinicopathological features and programmed death-ligand 1 expression in thyroid carcinoma. Endocrine 2022. [PMID: 35366156 DOI: 10.1007/s12020-022-03031-w] [Reference Citation Analysis]
29 Wu AM, Pandit-Taskar N. ImmunoPET: harnessing antibodies for imaging immune cells. Mol Imaging Biol 2021. [PMID: 34550529 DOI: 10.1007/s11307-021-01652-7] [Reference Citation Analysis]
30 Papworth KE, Arroyo VM, Styring E, Zaikova O, Melin BS, Lupo PJ. Soft‐tissue sarcoma in adolescents and young adults compared with older adults: A report among 5000 patients from the Scandinavian Sarcoma Group Central Register. Cancer 2019;125:3595-602. [DOI: 10.1002/cncr.32367] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
31 Zhou N, Li T, Liang M, Ren F, Ni H, Liu W, Shi T, Xu D, Chen Q, Yu H, Song Z, Zu L, Li S, Xu S. Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement. Front Oncol 2022;12:848779. [PMID: 35223529 DOI: 10.3389/fonc.2022.848779] [Reference Citation Analysis]
32 Sové RJ, Jafarnejad M, Zhao C, Wang H, Ma H, Popel AS. QSP-IO: A Quantitative Systems Pharmacology Toolbox for Mechanistic Multiscale Modeling for Immuno-Oncology Applications. CPT Pharmacometrics Syst Pharmacol 2020;9:484-97. [PMID: 32618119 DOI: 10.1002/psp4.12546] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
33 Bie F, Tian H, Sun N, Zang R, Zhang M, Song P, Liu L, Peng Y, Bai G, Zhou B, Gao S. Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC. Front Oncol 2022;12:769124. [PMID: 35223466 DOI: 10.3389/fonc.2022.769124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Gascón M, Isla D, Cruellas M, Gálvez EM, Lastra R, Ocáriz M, Paño JR, Ramírez A, Sesma A, Torres-Ramón I, Yubero A, Pardo J, Martínez-Lostao L. Intratumoral Versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One? Cells 2020;9:E1525. [PMID: 32580514 DOI: 10.3390/cells9061525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Naing A, Infante J, Goel S, Burris H, Black C, Marshall S, Achour I, Barbee S, May R, Morehouse C, Pollizzi K, Song X, Steele K, Elgeioushi N, Walcott F, Karakunnel J, LoRusso P, Weise A, Eder J, Curti B, Oberst M. Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies. J Immunother Cancer 2019;7:225. [PMID: 31439037 DOI: 10.1186/s40425-019-0665-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
36 Diab A, Tykodi SS, Daniels GA, Maio M, Curti BD, Lewis KD, Jang S, Kalinka E, Puzanov I, Spira AI, Cho DC, Guan S, Puente E, Nguyen T, Hoch U, Currie SL, Lin W, Tagliaferri MA, Zalevsky J, Sznol M, Hurwitz ME. Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. J Clin Oncol 2021;:JCO2100675. [PMID: 34255535 DOI: 10.1200/JCO.21.00675] [Reference Citation Analysis]
37 Albrecht T, Brinkmann F, Albrecht M, Lonsdorf AS, Mehrabi A, Hoffmann K, Kulu Y, Charbel A, Vogel MN, Rupp C, Köhler B, Springfeld C, Schirmacher P, Roessler S, Goeppert B. Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer. Cancers (Basel) 2021;13:1682. [PMID: 33918309 DOI: 10.3390/cancers13071682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Wu P, Sun W, Zhang H. An immune-related prognostic signature for thyroid carcinoma to predict survival and response to immune checkpoint inhibitors. Cancer Immunol Immunother 2021. [PMID: 34398303 DOI: 10.1007/s00262-021-03020-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Dieu-Nosjean MC, Caux C. [The biology of PD1 and CTLA-4 as immunotherapeutic targets and the issue of biomarkers]. Med Sci (Paris) 2019;35:957-65. [PMID: 31903900 DOI: 10.1051/medsci/2019192] [Reference Citation Analysis]
40 Wang H, Chen S, Meng D, Wu C, Zhu J, Jiang M, Ning J, Wu S, Wu L, Li J, Chen B, Zhao S, Li W, Yu J, Fang Q, Zhu J, Zhao W, He Y, Zhou C. Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma. Onco Targets Ther 2021;14:2953-65. [PMID: 33976553 DOI: 10.2147/OTT.S294993] [Reference Citation Analysis]
41 Rojko L, Megyesfalvi Z, Czibula E, Reiniger L, Teglasi V, Szegedi Z, Szallasi Z, Dome B, Moldvay J. Longitudinal analysis of complete blood count parameters in advanced-stage lung cancer patients. Thorac Cancer 2020;11:3193-204. [PMID: 32941706 DOI: 10.1111/1759-7714.13642] [Reference Citation Analysis]
42 Wessolly M, Stephan-Falkenau S, Streubel A, Werner R, Borchert S, Griff S, Mairinger E, Walter RFH, Bauer T, Eberhardt WEE, Blum TG, Schmid KW, Kollmeier J, Mairinger T, Mairinger FD. A Novel Epitope Quality-Based Immune Escape Mechanism Reveals Patient's Suitability for Immune Checkpoint Inhibition. Cancer Manag Res 2020;12:7881-90. [PMID: 32922086 DOI: 10.2147/CMAR.S258396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Shimada Y, Matsubayashi J, Kudo Y, Maehara S, Takeuchi S, Hagiwara M, Kakihana M, Ohira T, Nagao T, Ikeda N. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer. Sci Rep 2021;11:7830. [PMID: 33837261 DOI: 10.1038/s41598-021-87575-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Pu D, Yin L, Huang L, Qin C, Zhou Y, Wu Q, Li Y, Zhou Q, Li L. Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer. Front Oncol 2021;11:637504. [PMID: 33718229 DOI: 10.3389/fonc.2021.637504] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
45 Millian DE, Saldarriaga OA, Wanninger T, Burks JK, Rafati YN, Gosnell J, Stevenson HL. Cutting-Edge Platforms for Analysis of Immune Cells in the Hepatic Microenvironment-Focus on Tumor-Associated Macrophages in Hepatocellular Carcinoma. Cancers (Basel) 2022;14:1861. [PMID: 35454766 DOI: 10.3390/cancers14081861] [Reference Citation Analysis]
46 Luo Q, Zhang Y, Wang Z, Sun Y, Shi L, Yu Y, Shi J, Hu Z, Wang F. A novel peptide-based probe 99mTc-PEG6-RD-PDP2 for the molecular imaging of tumor PD-L2 expression. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.02.068] [Reference Citation Analysis]
47 Tan Z, Fu S, Feng R, Huang Y, Li N, Wang H, Wang J, Wang J. Identification of Potential Biomarkers for Progression and Prognosis of Bladder Cancer by Comprehensive Bioinformatics Analysis. Journal of Oncology 2022;2022:1-17. [DOI: 10.1155/2022/1802706] [Reference Citation Analysis]
48 Sugino K, Tamura R, Nakaoka H, Yachida N, Yamaguchi M, Mori Y, Yamawaki K, Suda K, Ishiguro T, Adachi S, Isobe M, Yamaguchi M, Kashima K, Motoyama T, Inoue I, Yoshihara K, Enomoto T. Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients. Sci Rep 2019;9:17808. [PMID: 31780705 DOI: 10.1038/s41598-019-54116-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
49 Zhang C, Fan Y, Che X, Zhang M, Li Z, Li C, Wang S, Wen T, Hou K, Shao X, Liu Y, Qu X. Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28. Front Oncol 2020;10:760. [PMID: 32528882 DOI: 10.3389/fonc.2020.00760] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
50 Zou J, Xia H, Zhang C, Xu H, Tang Q, Zhu G, Li J, Bi F. Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy. Cancer Sci 2021;112:2664-78. [PMID: 33934451 DOI: 10.1111/cas.14932] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Refolo MG, Lotesoriere C, Messa C, Caruso MG, D'Alessandro R. Integrated immune gene expression signature and molecular classification in gastric cancer: New insights. J Leukoc Biol 2020;108:633-46. [PMID: 32170872 DOI: 10.1002/JLB.4MR0120-221R] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
52 Fu H, Lu J, Zhang X, Wang B, Sun Y, Lei Y, Shen F, Kassegne K, Han ET, Cheng Y. Identification of the Recombinant Plasmodium vivax Surface-Related Antigen as a Possible Immune Evasion Factor Against Human Splenic Fibroblasts by Targeting ITGB1. Front Cell Dev Biol 2021;9:764109. [PMID: 34938733 DOI: 10.3389/fcell.2021.764109] [Reference Citation Analysis]
53 Sato Y, Tanaka S, Kinoshita M, Takemura S, Shinkawa H, Kokudo T, Hasegawa K, Tanaka H, Yoshimoto H, Mori A, Yamamura M, Sasaki M, Harada K, Kubo S. Immunosuppressive tumor microenvironment in occupational cholangiocarcinoma: Supportive evidence for the efficacy of immune checkpoint inhibitor therapy. J Hepatobiliary Pancreat Sci 2020;27:860-9. [PMID: 32506715 DOI: 10.1002/jhbp.788] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
54 Hogan KA, Chini CCS, Chini EN. The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases. Front Immunol 2019;10:1187. [PMID: 31214171 DOI: 10.3389/fimmu.2019.01187] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 25.7] [Reference Citation Analysis]
55 Nakata J, Isohashi K, Oka Y, Nakajima H, Morimoto S, Fujiki F, Oji Y, Tsuboi A, Kumanogoh A, Hashimoto N, Hatazawa J, Sugiyama H. Imaging Assessment of Tumor Response in the Era of Immunotherapy. Diagnostics (Basel) 2021;11:1041. [PMID: 34198874 DOI: 10.3390/diagnostics11061041] [Reference Citation Analysis]
56 Pandit-Taskar N, Postow MA. Immune-Directed Molecular Imaging Biomarkers. Semin Nucl Med 2020;50:584-603. [PMID: 33059826 DOI: 10.1053/j.semnuclmed.2020.06.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
57 Song Y, Li Z, Xue W, Zhang M. Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. Immunotherapy 2019;11:515-29. [DOI: 10.2217/imt-2018-0173] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
58 Cheng K, Wang Y, Chen Y, Zhu J, Qi X, Wang Y, Zou Y, Lu Q, Li Z. Multisite Radiotherapy Combined With Tislelizumab for Metastatic Castration-Resistant Prostate Cancer With Second-Line and Above Therapy Failure: Study Protocol for an Open-Label, Single-Arm, Phase Ib/II Study. Front Oncol 2022;12:888707. [DOI: 10.3389/fonc.2022.888707] [Reference Citation Analysis]
59 Appleman LJ. Multifactorial, Biomarker-Based Predictive Models for Immunotherapy Response Enter the Arena. J Natl Cancer Inst 2021;113:7-8. [PMID: 32516413 DOI: 10.1093/jnci/djaa077] [Reference Citation Analysis]
60 Wang M, Wang B, Fang W. CD8+ T-cell percentage increases in diffuse large B-cell lymphoma patients receiving mannatide combined with standard regimens. J Clin Pharm Ther 2021;46:832-7. [PMID: 33569786 DOI: 10.1111/jcpt.13370] [Reference Citation Analysis]
61 Yi M, Niu M, Xu L, Luo S, Wu K. Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol 2021;14:10. [PMID: 33413496 DOI: 10.1186/s13045-020-01027-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 18.0] [Reference Citation Analysis]
62 Wang S, Zhu H, Ding J, Wang F, Meng X, Ding L, Zhang Y, Li N, Yao S, Sheng X, Yang Z. Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I-Labeled Toripalimab: A Pilot Clinical Translation Study. Clin Nucl Med 2021;46:382-8. [PMID: 33512952 DOI: 10.1097/RLU.0000000000003520] [Reference Citation Analysis]
63 Kang DH, Park CK, Chung C, Oh IJ, Kim YC, Park D, Kim J, Kwon GC, Kwon I, Sun P, Shin EC, Lee JE. Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors. Immune Netw 2020;20:e27. [PMID: 32655975 DOI: 10.4110/in.2020.20.e27] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
64 Zhong W, Liu X, Zhu Z, Li Q, Li K. High levels of Tim-3+Foxp3+Treg cells in the tumor microenvironment is a prognostic indicator of poor survival of diffuse large B cell lymphoma patients. Int Immunopharmacol 2021;96:107662. [PMID: 33864956 DOI: 10.1016/j.intimp.2021.107662] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Lee EY, Kulkarni RP. Circulating biomarkers predictive of tumor response to cancer immunotherapy. Expert Rev Mol Diagn 2019;19:895-904. [PMID: 31469965 DOI: 10.1080/14737159.2019.1659728] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
66 Al-jussani GN, Alsughayer A, Yousuf MS, Mullahuwash Y, Dabbagh T, Sughayer MA. The clinicopathological features of programmed death ligand-1 expression in colorectal carcinoma. Int J Biol Markers. [DOI: 10.1177/03936155221104122] [Reference Citation Analysis]
67 Wang X, Chai Z, Li Y, Long F, Hao Y, Pan G, Liu M, Li B. Identification of Potential Biomarkers for Anti-PD-1 Therapy in Melanoma by Weighted Correlation Network Analysis. Genes (Basel) 2020;11:E435. [PMID: 32316408 DOI: 10.3390/genes11040435] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
68 Liu F, Qin L, Liao Z, Song J, Yuan C, Liu Y, Wang Y, Xu H, Zhang Q, Pei Y, Zhang H, Pan Y, Chen X, Zhang Z, Zhang W, Zhang B. Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma. Exp Hematol Oncol 2020;9:10. [PMID: 32509418 DOI: 10.1186/s40164-020-00165-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
69 Karakas C, Francis AM, Ha MJ, Wingate HF, Meena RA, Yi M, Rasaputra KS, Barrera AMG, Arun B, Do KA, Sahin A, Keyomarsi K, Hunt KK. Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. Ann Surg 2021;274:e150-9. [PMID: 31436549 DOI: 10.1097/SLA.0000000000003551] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
70 Clifton GT, Peoples AGE. Immunotherapy as a partner for HER2-directed therapies. Expert Rev Anticancer Ther 2021;21:739-46. [PMID: 33666116 DOI: 10.1080/14737140.2021.1894932] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Cilibrasi C, Papanastasopoulos P, Samuels M, Giamas G. Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies. Int J Mol Sci 2021;22:12015. [PMID: 34769447 DOI: 10.3390/ijms222112015] [Reference Citation Analysis]
72 Kim H, Jang J, Heo YJ, Kim B, Jung H, Jang Y, Kang SY, Kim ST, Lee J, Kang WK, Kim K. PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation. Virchows Arch 2020;476:243-50. [DOI: 10.1007/s00428-019-02653-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
73 Zhang Y, Chen Y, Papakonstantinou A, Tsagkozis P, Linder-stragliotto C, Haglund F. Evaluation of PD-L1 Expression in Undifferentiated Pleomorphic Sarcomas, Liposarcomas and Chondrosarcomas. Biomolecules 2022;12:292. [DOI: 10.3390/biom12020292] [Reference Citation Analysis]
74 Bai X, Yi M, Jiao Y, Chu Q, Wu K. Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor. Onco Targets Ther 2019;12:9527-38. [PMID: 31807028 DOI: 10.2147/OTT.S224013] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 10.3] [Reference Citation Analysis]
75 Rezasoltani S, Yadegar A, Asadzadeh Aghdaei H, Reza Zali M. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors. Cancer Med 2021;10:1141-54. [PMID: 33369247 DOI: 10.1002/cam4.3694] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
76 Valentinuzzi D, Vrankar M, Boc N, Ahac V, Zupancic Z, Unk M, Skalic K, Zagar I, Studen A, Simoncic U, Eickhoff J, Jeraj R. [18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab. Radiol Oncol 2020;54:285-94. [PMID: 32726293 DOI: 10.2478/raon-2020-0042] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
77 Wang X, Cao K, Guo E, Mao X, An C, Guo L, Zhang C, Guo J, Yang X, Sun J, Yang W, Li X, Miao S. Assessment of immune status of laryngeal squamous cell carcinoma can predict prognosis and guide treatment. Cancer Immunol Immunother 2021. [PMID: 34643766 DOI: 10.1007/s00262-021-03071-7] [Reference Citation Analysis]
78 Macek Jilkova Z, Aspord C, Decaens T. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. Cancers (Basel) 2019;11:E1554. [PMID: 31615069 DOI: 10.3390/cancers11101554] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
79 Batur S, Dulger O, Durak S, Yumuk PF, Caglar HB, Bozkurtlar E, Bozkurt S, Tastekin E, Cicin I, Ahiskali R, Rzazade R, Cakir A, Oz B. Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases. Bosn J Basic Med Sci 2020;20:329-35. [PMID: 31999935 DOI: 10.17305/bjbms.2019.4474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
80 Kim S, Lee JW, Park YS. The Application of Next-Generation Sequencing to Define Factors Related to Oral Cancer and Discover Novel Biomarkers. Life (Basel) 2020;10:E228. [PMID: 33023080 DOI: 10.3390/life10100228] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
81 Deng Z, Teng YJ, Zhou Q, Ouyang ZG, Hu YX, Long HP, Hu MJ, Mei S, Lin FX, Dai XJ, Zhang BY, Feng T, Tian XF. Shuyu pills inhibit immune escape and enhance chemosensitization in hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(11): 1725-1740 [PMID: 34853646 DOI: 10.4251/wjgo.v13.i11.1725] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
82 Luo XY, Wu KM, He XX. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. J Exp Clin Cancer Res 2021;40:172. [PMID: 34006331 DOI: 10.1186/s13046-021-01968-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
83 Inanaga S, Igase M, Sakai Y, Tanabe M, Shimonohara N, Itamoto K, Nakaichi M, Mizuno T. Mismatch repair deficiency in canine neoplasms. Vet Pathol 2021;58:1058-63. [PMID: 34538134 DOI: 10.1177/03009858211022704] [Reference Citation Analysis]
84 Chen Y, Wang Y, Luo H, Meng X, Zhu W, Wang D, Zeng H, Zhang H. The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China. Exp Hematol Oncol 2020;9:17. [PMID: 32775040 DOI: 10.1186/s40164-020-00173-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
85 Viale G, Morganti S, Ferraro E, Zagami P, Marra A, Curigliano G. What therapies are on the horizon for HER2 positive breast cancer? Expert Rev Anticancer Ther 2019;19:811-22. [PMID: 31448640 DOI: 10.1080/14737140.2019.1660164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
86 Ganesan S, Mehnert J. Biomarkers for Response to Immune Checkpoint Blockade. Annu Rev Cancer Biol 2020;4:331-51. [DOI: 10.1146/annurev-cancerbio-030419-033604] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
87 Wu Y, Yang L, Zhang L, Zheng X, Xu H, Wang K, Weng X. Identification of a Four-Gene Signature Associated with the Prognosis Prediction of Lung Adenocarcinoma Based on Integrated Bioinformatics Analysis. Genes 2022;13:238. [DOI: 10.3390/genes13020238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
88 Schulz GB, Todorova R, Braunschweig T, Rodler S, Volz Y, Eismann L, Pfitzinger P, Jokisch F, Buchner A, Stief C, Mayr D, Casuscelli J. PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue? Urol Oncol 2021:S1078-1439(21)00260-X. [PMID: 34261585 DOI: 10.1016/j.urolonc.2021.06.001] [Reference Citation Analysis]
89 Russo A, Incorvaia L, Malapelle U, Del Re M, Capoluongo E, Vincenzi B, Chiari R, Cortesi L, Danesi R, Florena AM, Fontanini G, Gori S, Marchetti A, Normanno N, Pinto C, Sangiolo D, Silvestris N, Tagliaferri P, Tallini G, Cinieri S, Beretta G. The Tumor-Agnostic Treatment For Patients with Solid Tumors: a Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBIOC-SIF Italian Scientific Societies. Crit Rev Oncol Hematol 2021;:103436. [PMID: 34371157 DOI: 10.1016/j.critrevonc.2021.103436] [Reference Citation Analysis]
90 Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer 2019;18:155. [PMID: 31690319 DOI: 10.1186/s12943-019-1091-2] [Cited by in Crossref: 189] [Cited by in F6Publishing: 206] [Article Influence: 63.0] [Reference Citation Analysis]
91 Huo J, Wang Y, Fu W, Lu N, Liu Z. The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. Front Immunol 2022;13:956090. [DOI: 10.3389/fimmu.2022.956090] [Reference Citation Analysis]
92 Zhao H, Chen C, Song H, Wang X, Zhang L, Zhao H, He J. Single-cell RNA Sequencing Analysis Reveals New Immune Disorder Complexities in Hypersplenism. Front Immunol 2022;13:921900. [DOI: 10.3389/fimmu.2022.921900] [Reference Citation Analysis]
93 Yin Z, Yu M, Ma T, Zhang C, Huang S, Karimzadeh MR, Momtazi-Borojeni AA, Chen S. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1. J Immunother Cancer 2021;9:e001698. [PMID: 33472857 DOI: 10.1136/jitc-2020-001698] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
94 Zhang ZS, Yang RH, Yao X, Cheng YY, Shi HX, Yao CY, Gao ZX, Qi DF, Zhang WK, Dou YY, Guo J, Hu MW, Zhao H, Fang D. HGF/c-MET pathway contributes to cisplatin-mediated PD-L1 expression in hepatocellular carcinoma. Cell Biol Int 2021. [PMID: 34486197 DOI: 10.1002/cbin.11697] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Yang H, Xiong X, Li H. Development and Interpretation of a Genomic Instability Derived lncRNAs Based Risk Signature as a Predictor of Prognosis for Clear Cell Renal Cell Carcinoma Patients. Front Oncol 2021;11:678253. [PMID: 34094983 DOI: 10.3389/fonc.2021.678253] [Reference Citation Analysis]
96 Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J. Ovarian Cancer Immunotherapy and Personalized Medicine. Int J Mol Sci 2021;22:6532. [PMID: 34207103 DOI: 10.3390/ijms22126532] [Reference Citation Analysis]
97 Zhan R, Wang S, Guo W, Gao X, Liu X, Xu K, Tang B. A simple, rapid and low-cost qPCR assay for evaluating the severity of exosomal PD-L1-mediated T cell exhaustion in blood samples. Chem Commun (Camb) 2021. [PMID: 34931643 DOI: 10.1039/d1cc06496g] [Reference Citation Analysis]
98 Fan Y, Zhou Y, Lou M, Li X, Zhu X, Yuan K. m6A Regulator-Mediated Methylation Modification Patterns and Characterisation of Tumour Microenvironment Infiltration in Non-Small Cell Lung Cancer. JIR 2022;Volume 15:1969-89. [DOI: 10.2147/jir.s356841] [Reference Citation Analysis]
99 Rodríguez J, Avila J, Rolfo C, Ruíz-Patiño A, Russo A, Ricaurte L, Ordóñez-Reyes C, Arrieta O, Zatarain-Barrón ZL, Recondo G, Cardona AF. When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review. Oncol Ther 2021;9:89-110. [PMID: 33689160 DOI: 10.1007/s40487-021-00144-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
100 Li Z, Feng Y, Li P, Wang S, Liu X, Xia S. CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma. IJGM 2022;Volume 15:3809-26. [DOI: 10.2147/ijgm.s352851] [Reference Citation Analysis]
101 Tannir NM, Cho DC, Diab A, Sznol M, Bilen MA, Balar AV, Grignani G, Puente E, Tang L, Chien D, Hoch U, Choudhury A, Yu D, Currie SL, Tagliaferri MA, Zalevsky J, Siefker-Radtke AO, Hurwitz ME. Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. J Immunother Cancer 2022;10:e004419. [PMID: 35444058 DOI: 10.1136/jitc-2021-004419] [Reference Citation Analysis]
102 Xu JL. Wilms Tumor 1-Associated Protein Expression Is Linked to a T-Cell-Inflamed Phenotype in Pancreatic Cancer. Dig Dis Sci 2022. [PMID: 35859262 DOI: 10.1007/s10620-022-07620-7] [Reference Citation Analysis]
103 Liu S, Zhu Y, Zhang C, Liu J, Lv H, Zhang G, Kang X. Soluble programmed death-1 (sPD-1) and programmed death ligand 1 (sPD-L1) as potential biomarkers for the diagnosis and prognosis of glioma patients. J Med Biochem 2020;39:444-51. [PMID: 33312060 DOI: 10.5937/jomb0-24692] [Reference Citation Analysis]
104 An Y, Wu Z, Wang N, Yang Z, Li Y, Xu B, Sun M. Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J Transl Med 2020;18:235. [PMID: 32532255 DOI: 10.1186/s12967-020-02404-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
105 Yılmaz O, Pankaj A, Neyez A, Rickelt S, Taylor M, Lang ER, Leijsen L, Dinaux A, Shroff SG, Crotty R, Zhang ML, Cerda S, Zhao Q, Ferrone C, Ting DT, Patil DT, Yilmaz O, Berger D, Deshpande V. Programmed death-ligand 1 expression in the immune compartment of colon carcinoma. Mod Pathol 2022. [PMID: 35773332 DOI: 10.1038/s41379-022-01128-1] [Reference Citation Analysis]
106 Ahn S, Woo JW, Kim H, Cho EY, Kim A, Kim JY, Kim C, Lee HJ, Lee JS, Bae YK, Kwon Y, Kim WS, Park SY. Programmed Death Ligand 1 Immunohistochemistry in Triple-Negative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability. J Breast Cancer 2021;24:266-79. [PMID: 34128367 DOI: 10.4048/jbc.2021.24.e29] [Reference Citation Analysis]
107 Chigoho DM, Lecocq Q, Awad RM, Breckpot K, Devoogdt N, Keyaerts M, Caveliers V, Xavier C, Bridoux J. Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimide-Cysteine Chemistry. Pharmaceuticals (Basel) 2021;14:550. [PMID: 34201323 DOI: 10.3390/ph14060550] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Nagata M, Kosaka A, Yajima Y, Yasuda S, Ohara M, Ohara K, Harabuchi S, Hayashi R, Funakoshi H, Ueda J, Kumai T, Nagato T, Oikawa K, Harabuchi Y, Esteban C, Ohkuri T, Kobayashi H. A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment. Cancer Immunol Immunother 2021;70:2301-12. [PMID: 33507344 DOI: 10.1007/s00262-021-02864-0] [Reference Citation Analysis]
109 Xu H, Chen Y, Li Z, Zhang H, Liu J, Han J. The hypoxia-inducible factor 1 inhibitor LW6 mediates the HIF-1α/PD-L1 axis and suppresses tumor growth of hepatocellular carcinoma in vitro and in vivo. Eur J Pharmacol 2022;930:175154. [PMID: 35868447 DOI: 10.1016/j.ejphar.2022.175154] [Reference Citation Analysis]
110 Li W, Xu M, Li Y, Huang Z, Zhou J, Zhao Q, Le K, Dong F, Wan C, Yi P. Comprehensive analysis of the association between tumor glycolysis and immune/inflammation function in breast cancer. J Transl Med 2020;18:92. [PMID: 32070368 DOI: 10.1186/s12967-020-02267-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
111 Aili A, Wen J, Xue L, Wang J. Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell Carcinoma. Front Oncol 2021;11:712765. [PMID: 34447697 DOI: 10.3389/fonc.2021.712765] [Reference Citation Analysis]
112 Zhang R, Zhong L, Liu X, Liu X, Chen Q, Wu P, He J, Li Y, Zhao Y, Liu Z, Zu Y, Huang Y, Wang B. Microfluidic PLGA microcapsules with PD-L1 aptamers and docetaxel encapsulation for enhancing tumor immunity. Applied Materials Today 2022;27:101484. [DOI: 10.1016/j.apmt.2022.101484] [Reference Citation Analysis]
113 Zheng X, Liu Z, Mi M, Wen Q, Wu G, Zhang L. Disulfiram Improves the Anti-PD-1 Therapy Efficacy by Regulating PD-L1 Expression via Epigenetically Reactivation of IRF7 in Triple Negative Breast Cancer. Front Oncol 2021;11:734853. [PMID: 34858816 DOI: 10.3389/fonc.2021.734853] [Reference Citation Analysis]
114 Tan KW, Chacko AM, Chew V. PD-1 expression and its significance in tumour microenvironment of hepatocellular carcinoma. Transl Gastroenterol Hepatol 2019;4:51. [PMID: 31463410 DOI: 10.21037/tgh.2019.06.08] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
115 Alderdice M, Craig SG, Humphries MP, Gilmore A, Johnston N, Bingham V, Coyle V, Senevirathne S, Longley DB, Loughrey MB, McQuaid S, James JA, Salto-Tellez M, Lawler M, McArt DG. Evolutionary genetic algorithm identifies IL2RB as a potential predictive biomarker for immune-checkpoint therapy in colorectal cancer. NAR Genom Bioinform 2021;3:lqab016. [PMID: 33928242 DOI: 10.1093/nargab/lqab016] [Reference Citation Analysis]
116 Siraj AK, Parvathareddy SK, Pratheeshkumar P, Divya SP, Al-Sobhi SS, Al-Dayel F, Al-Kuraya KS. PD-L1 Is an Independent Prognostic Marker in Middle Eastern PTC and Its Expression Is Upregulated by BRAFV600E Mutation. Cancers (Basel) 2021;13:555. [PMID: 33535609 DOI: 10.3390/cancers13030555] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Bridge JA, Lee JC, Daud A, Wells JW, Bluestone JA. Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. Front Med (Lausanne) 2018;5:351. [PMID: 30631766 DOI: 10.3389/fmed.2018.00351] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
118 Calderaro J, Ziol M, Paradis V, Zucman-rossi J. Molecular and histological correlations in liver cancer. Journal of Hepatology 2019;71:616-30. [DOI: 10.1016/j.jhep.2019.06.001] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 24.7] [Reference Citation Analysis]
119 Yi M, Dong B, Chu Q, Wu K. Immune pressures drive the promoter hypermethylation of neoantigen genes. Exp Hematol Oncol 2019;8:32. [PMID: 31799063 DOI: 10.1186/s40164-019-0156-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
120 Dudnik E, Moskovitz M, Rottenberg Y, Lobachov A, Mandelboim R, Shochat T, Urban D, Wollner M, Nechushtan H, Rotem O, Zer A, Daher S, Bar J; Israel Lung Cancer Group. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data. Oncoimmunology 2021;10:1865653. [PMID: 33552685 DOI: 10.1080/2162402X.2020.1865653] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
121 Huang Z, Chen Y, Zhang J, Li W, Shi M, Qiao M, Zhao X, Hu H, Chen D. Laser/GSH-Activatable Oxaliplatin/Phthalocyanine-Based Coordination Polymer Nanoparticles Combining Chemophotodynamic Therapy to Improve Cancer Immunotherapy. ACS Appl Mater Interfaces 2021;13:39934-48. [PMID: 34396771 DOI: 10.1021/acsami.1c11327] [Reference Citation Analysis]
122 Jeong E, Lee Y, Kim Y, Lee J, Yoon S. Analysis of Cross-Association between mRNA Expression and RNAi Efficacy for Predictive Target Discovery in Colon Cancers. Cancers (Basel) 2020;12:E3091. [PMID: 33114107 DOI: 10.3390/cancers12113091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
123 Hou F, Pan Z, Yang R, Zhi F, Bi Y. Gold digging: Searching for gut microbiota that enhances antitumor immunity. J Cell Physiol 2021;236:5495-511. [PMID: 33452716 DOI: 10.1002/jcp.30272] [Reference Citation Analysis]
124 Cesano A, Marincola FM, Thurin M. Status of Immune Oncology: Challenges and Opportunities. In: Thurin M, Cesano A, Marincola FM, editors. Biomarkers for Immunotherapy of Cancer. New York: Springer; 2020. pp. 3-21. [DOI: 10.1007/978-1-4939-9773-2_1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
125 Wang J, Cao L, Xu S. Sarcopenia affects clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients: A systematic review and meta-analysis. International Immunopharmacology 2020;88:106907. [DOI: 10.1016/j.intimp.2020.106907] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
126 Cierna Z, Smolkova B, Cholujova D, Gronesova P, Miklikova S, Cihova M, Plava J, Mego M. Decreased levels of circulating cytokines VEGF, TNF-β and IL-15 indicate PD-L1 overexpression in tumours of primary breast cancer patients. Sci Rep 2021;11:1294. [PMID: 33446741 DOI: 10.1038/s41598-020-80351-9] [Reference Citation Analysis]
127 Brown DG, Wobst HJ. A Decade of FDA-Approved Drugs (2010-2019): Trends and Future Directions. J Med Chem 2021;64:2312-38. [PMID: 33617254 DOI: 10.1021/acs.jmedchem.0c01516] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
128 Kim E, Ahn H, Park H. A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer. Mamm Genome 2021;32:223-31. [PMID: 33783613 DOI: 10.1007/s00335-021-09867-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
129 Ahn S, Kim KM. PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy. Mod Pathol 2021;34:1719-27. [PMID: 34002009 DOI: 10.1038/s41379-021-00823-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
130 Peng X, Zheng T, Guo Y, Zhu Y. Amino acid metabolism genes associated with immunotherapy responses and clinical prognosis of colorectal cancer. Front Mol Biosci 2022;9:955705. [DOI: 10.3389/fmolb.2022.955705] [Reference Citation Analysis]
131 Angelicola S, Ruzzi F, Landuzzi L, Scalambra L, Gelsomino F, Ardizzoni A, Nanni P, Lollini PL, Palladini A. IFN-γ and CD38 in Hyperprogressive Cancer Development. Cancers (Basel) 2021;13:309. [PMID: 33467713 DOI: 10.3390/cancers13020309] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
132 Zhang J, Han X, Lin L, Chen J, Wang F, Ding Q, Hao L, Wang L, Wei J, Wang Y, Pan Y, Isaguliants M. Unraveling the Expression Patterns of Immune Checkpoints Identifies New Subtypes and Emerging Therapeutic Indicators in Lung Adenocarcinoma. Oxidative Medicine and Cellular Longevity 2022;2022:1-19. [DOI: 10.1155/2022/3583985] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Yang D, Li H, Chen Y, Li C, Ren W, Huang Y. A Pan-Cancer Analysis of the Oncogenic Role of BCL7B: A Potential Biomarker for Prognosis and Immunotherapy. Front Genet 2022;13:906174. [DOI: 10.3389/fgene.2022.906174] [Reference Citation Analysis]
134 Zhao Y, Cao Y, Chen Y, Wu L, Hang H, Jiang C, Zhou X. B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy. Immunology 2021. [PMID: 34115389 DOI: 10.1111/imm.13384] [Reference Citation Analysis]
135 Gatalica Z, Vranic S, Krušlin B, Poorman K, Stafford P, Kacerovska D, Senarathne W, Florento E, Contreras E, Leary A, Choi A, In GK. Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease. Cancer Med 2020;9:1441-50. [PMID: 31899853 DOI: 10.1002/cam4.2820] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
136 Gennen K, Käsmann L, Taugner J, Eze C, Karin M, Roengvoraphoj O, Neumann J, Tufman A, Orth M, Reu S, Belka C, Manapov F. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Radiat Oncol 2020;15:5. [PMID: 31898519 DOI: 10.1186/s13014-019-1453-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
137 Sudoyo AW, Kurniawan AN, Kusumo GD, Putra TP, Rexana FA, Yunus M, Budiyati AD, Kurniawan D, Utama A, Utomo AR. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression. Asian Pac J Cancer Prev 2019;20:3421-7. [PMID: 31759368 DOI: 10.31557/APJCP.2019.20.11.3421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
138 Cari L, De Rosa F, Petrillo MG, Migliorati G, Nocentini G, Riccardi C. Identification of 15 T Cell Restricted Genes Evaluates T Cell Infiltration of Human Healthy Tissues and Cancers and Shows Prognostic and Predictive Potential. Int J Mol Sci 2019;20:E5242. [PMID: 31652661 DOI: 10.3390/ijms20205242] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
139 Makuku R, Khalili N, Razi S, Keshavarz-Fathi M, Rezaei N. Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy. J Immunol Res 2021;2021:6661406. [PMID: 33681388 DOI: 10.1155/2021/6661406] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
140 Wessolly M, Stephan-Falkenau S, Streubel A, Wiesweg M, Borchert S, Mairinger E, Kollmeier J, Reis H, Bauer T, Schmid KW, Mairinger T, Schuler M, Mairinger FD. Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy. BMC Cancer 2022;22:46. [PMID: 34996407 DOI: 10.1186/s12885-021-09111-w] [Reference Citation Analysis]
141 Marcelis L, Antoranz A, Delsupehe AM, Biesemans P, Ferreiro JF, Debackere K, Vandenberghe P, Verhoef G, Gheysens O, Cattoretti G, Bosisio FM, Sagaert X, Dierickx D, Tousseyn T. In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy. Cancer Immunol Immunother 2020;69:1751-66. [PMID: 32335702 DOI: 10.1007/s00262-020-02575-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
142 Donnelly LL, Hogan TC, Lenahan SM, Nandagopal G, Eaton JG, Lebeau MA, McCann CL, Sarausky HM, Hampel KJ, Armstrong JD, Cameron MP, Sidiropoulos N, Deming P, Seward DJ. Functional assessment of somatic STK11 variants identified in primary human non-small cell lung cancers. Carcinogenesis 2021:bgab104. [PMID: 34849607 DOI: 10.1093/carcin/bgab104] [Reference Citation Analysis]
143 Barbari C, Fontaine T, Parajuli P, Lamichhane N, Jakubski S, Lamichhane P, Deshmukh RR. Immunotherapies and Combination Strategies for Immuno-Oncology. Int J Mol Sci 2020;21:E5009. [PMID: 32679922 DOI: 10.3390/ijms21145009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
144 Chen Y, Lai X. Modeling the effect of gut microbiome on therapeutic efficacy of immune checkpoint inhibitors against cancer. Math Biosci 2022;:108868. [PMID: 35753521 DOI: 10.1016/j.mbs.2022.108868] [Reference Citation Analysis]
145 Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18:60. [PMID: 30925919 DOI: 10.1186/s12943-019-0974-6] [Cited by in Crossref: 104] [Cited by in F6Publishing: 115] [Article Influence: 34.7] [Reference Citation Analysis]
146 Sobhani N, Corona SP, Roviello G, Bagby S, D'Angelo A, Iezzi G, Generali D. Immune-gene signature: a new tool for patient selection for checkpoint inhibitors? Future Oncol 2020;16:1327-30. [PMID: 32396404 DOI: 10.2217/fon-2020-0311] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
147 Niu M, Yi M, Li N, Luo S, Wu K. Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC. Exp Hematol Oncol 2021;10:18. [PMID: 33653420 DOI: 10.1186/s40164-021-00211-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
148 Pan C, Wu Q, Wang S, Mei Z, Zhang L, Gao X, Qian J, Xu Z, Zhang K, Su R, Guo D, Zhou L, Zheng S. Combination with Toll-like receptor 4 (TLR4) agonist reverses GITR agonism mediated M2 polarization of macrophage in Hepatocellular carcinoma. OncoImmunology 2022;11:2073010. [DOI: 10.1080/2162402x.2022.2073010] [Reference Citation Analysis]
149 Zhao X, Shao C. Radiotherapy-Mediated Immunomodulation and Anti-Tumor Abscopal Effect Combining Immune Checkpoint Blockade. Cancers (Basel) 2020;12:E2762. [PMID: 32992835 DOI: 10.3390/cancers12102762] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
150 Yi M, Xu L, Jiao Y, Luo S, Li A, Wu K. The role of cancer-derived microRNAs in cancer immune escape. J Hematol Oncol 2020;13:25. [PMID: 32222150 DOI: 10.1186/s13045-020-00848-8] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 23.0] [Reference Citation Analysis]
151 Shen X, Zhao Y, Liu G, Zhou H, Fan J, Zhang L, Li Y, Wang Y, Liang J, Xu Z. Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer. Life Sciences 2020;256:117923. [DOI: 10.1016/j.lfs.2020.117923] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
152 Hu C, Zhao L, Liu W, Fan S, Liu J, Liu Y, Liu X, Shu L, Liu X, Liu P, Deng C, Qiu Z, Chen C, Jiang Y, Liang Q, Yang L, Shao Y, He Q, Yu D, Zeng Y, Li Y, Pan Y, Zhang S, Shi S, Peng Y, Wu F. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers. J Immunother Cancer 2021;9:e003773. [PMID: 34887263 DOI: 10.1136/jitc-2021-003773] [Reference Citation Analysis]
153 Orth MF, Buecklein VL, Kampmann E, Subklewe M, Noessner E, Cidre-Aranaz F, Romero-Pérez L, Wehweck FS, Lindner L, Issels R, Kirchner T, Altendorf-Hofmann A, Grünewald TGP, Knösel T. A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas. Cancer Immunol Immunother 2020;69:1353-62. [PMID: 32222780 DOI: 10.1007/s00262-020-02552-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
154 Zhou X, Ren T, Zan H, Hua C, Guo X. Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets. Front Immunol 2022;13:864202. [DOI: 10.3389/fimmu.2022.864202] [Reference Citation Analysis]
155 Zhang A, Zhong G, Wang L, Cai R, Han R, Xu C, Chen S, Sun P, Chen H. Dynamic serum biomarkers to predict the efficacy of PD-1 in patients with nasopharyngeal carcinoma. Cancer Cell Int 2021;21:518. [PMID: 34583688 DOI: 10.1186/s12935-021-02217-y] [Reference Citation Analysis]
156 Qin S, Li A, Yi M, Yu S, Zhang M, Wu K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol 2019;12:27. [PMID: 30866992 DOI: 10.1186/s13045-019-0718-5] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 23.7] [Reference Citation Analysis]
157 Cai J, Zhou M, Xu J. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma. World J Surg Oncol 2021;19:241. [PMID: 34389000 DOI: 10.1186/s12957-021-02354-8] [Reference Citation Analysis]
158 Zhang Y, Zhao Y, Li Q, Wang Y. Macrophages, as a Promising Strategy to Targeted Treatment for Colorectal Cancer Metastasis in Tumor Immune Microenvironment. Front Immunol 2021;12:685978. [PMID: 34326840 DOI: 10.3389/fimmu.2021.685978] [Reference Citation Analysis]
159 Liu L, Yang M, Xu Q, Zhou M, Cheng Y, Xu H, Qin Y, Liu B. Killing efficiency affected by mutually modulated PD-1 and PD-L1 expression via NKT-hepatoma cell interactions. Immunotherapy 2021;13:113-23. [PMID: 33076728 DOI: 10.2217/imt-2020-0062] [Reference Citation Analysis]
160 Özdirik B, Jann H, Bischoff P, Fehrenbach U, Tacke F, Roderburg C, Wiedenmann B. PD-L1 - inhibitors in neuroendocrine neoplasia: Results from a real-life study. Medicine (Baltimore) 2021;100:e23835. [PMID: 33429744 DOI: 10.1097/MD.0000000000023835] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
161 Lamb LS, Sim HW, McCormack AI. Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy. Front Endocrinol (Lausanne) 2020;11:576027. [PMID: 33312158 DOI: 10.3389/fendo.2020.576027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
162 Zhang Y, Chen X, Mo S, Ma H, Lu Z, Yu S, Chen J. PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules. J Pathol Clin Res 2022;8:257-67. [PMID: 35037417 DOI: 10.1002/cjp2.259] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Tu J, Xu H, Ma L, Li C, Qin W, Chen X, Yi M, Sun L, Liu B, Yuan X. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells. Theranostics 2022;12:747-66. [PMID: 34976211 DOI: 10.7150/thno.65828] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
164 Ji X, Sui L, Song K, Lv T, Zhao H, Yao Q. PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer. Cancer Med 2021;10:4743-51. [PMID: 34076351 DOI: 10.1002/cam4.4034] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
165 Guan Y, Xu B, Sui Y, Chen Z, Luan Y, Jiang Y, Wei L, Long W, Zhao S, Han L, Xu D, Lin L, Guan Q. Pan-Cancer Analysis and Validation Reveals that D-Dimer-Related Genes are Prognostic and Downregulate CD8+ T Cells via TGF-Beta Signaling in Gastric Cancer. Front Mol Biosci 2022;9:790706. [DOI: 10.3389/fmolb.2022.790706] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
166 Cai D, Wang F, Wang C, Jin L. Phenotypic and Functional Analyses of B7S1 in Ovarian Cancer. Front Mol Biosci 2021;8:686803. [PMID: 34307455 DOI: 10.3389/fmolb.2021.686803] [Reference Citation Analysis]
167 Li Y, Shi X, Mao B, Wang L, Wu L, Li J, Jiao S. The genomic mutational landscape and its correlation with TMB, PD-L1 expression and CD8+ T cell infiltration in Chinese Lung Large Cell Neuroendocrine Carcinoma. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.01.007] [Reference Citation Analysis]
168 Wu K, Yi M, Qin S, Chu Q, Zheng X, Wu K. The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis. Exp Hematol Oncol 2019;8:26. [PMID: 31673481 DOI: 10.1186/s40164-019-0150-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
169 Wu D, Hacking S, Vitkovski T, Nasim M. Superpixel image segmentation of VISTA expression in colorectal cancer and its relationship to the tumoral microenvironment. Sci Rep 2021;11:17426. [PMID: 34465822 DOI: 10.1038/s41598-021-96417-1] [Reference Citation Analysis]
170 Parvathareddy SK, Siraj AK, Ahmed SO, Ghazwani LO, Aldughaither SM, Al-Dayel F, Tulbah A, Ajarim D, Al-Kuraya KS. PD-L1 Protein Expression in Middle Eastern Breast Cancer Predicts Favorable Outcome in Triple-Negative Breast Cancer. Cells 2021;10:229. [PMID: 33503961 DOI: 10.3390/cells10020229] [Reference Citation Analysis]
171 Belderbos RA, Aerts JGJV, Vroman H. Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment. Mol Ther Oncolytics 2019;13:67-81. [PMID: 31020037 DOI: 10.1016/j.omto.2019.03.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
172 Qin S, Dong B, Yi M, Chu Q, Wu K. Prognostic Values of TIM-3 Expression in Patients With Solid Tumors: A Meta-Analysis and Database Evaluation. Front Oncol 2020;10:1288. [PMID: 32850398 DOI: 10.3389/fonc.2020.01288] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
173 Liu Y, Chen L, Zhang S, Shu Y, Qi Q, Zhu M, Peng Y, Ling Y. Somatic mutations in genes associated with mismatch repair predict survival in patients with metastatic cancer receiving immune checkpoint inhibitors. Oncol Lett 2020;20:27. [PMID: 32774500 DOI: 10.3892/ol.2020.11888] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
174 Lian J, Zhang G, Zhang Y, Liu H, Zhang J, Nan P, Tian W. PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance. Dig Liver Dis 2022:S1590-8658(22)00140-2. [PMID: 35123909 DOI: 10.1016/j.dld.2022.01.128] [Reference Citation Analysis]
175 Liu D, Gao S, Zhai Y, Yang X, Zhai G. Research progress of tumor targeted drug delivery based on PD-1/PD-L1. International Journal of Pharmaceutics 2022. [DOI: 10.1016/j.ijpharm.2022.121527] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
176 Park KJ, Lee JL, Yoon SK, Heo C, Park BW, Kim JK. Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma. Eur Radiol 2020;30:5392-403. [PMID: 32394281 DOI: 10.1007/s00330-020-06847-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
177 Hofman P. The challenges of evaluating predictive biomarkers using small biopsy tissue samples and liquid biopsies from non-small cell lung cancer patients. J Thorac Dis 2019;11:S57-64. [PMID: 30775028 DOI: 10.21037/jtd.2018.11.85] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
178 Deacon DC, Smith EA, Judson-Torres RL. Molecular Biomarkers for Melanoma Screening, Diagnosis and Prognosis: Current State and Future Prospects. Front Med (Lausanne) 2021;8:642380. [PMID: 33937286 DOI: 10.3389/fmed.2021.642380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
179 Nie RC, Duan JL, Liang Y, Chen XJ, Chen YM, Luo TQ, Chen GM, Wang Y, Li YF. Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis. Immunotherapy 2020;12:1313-24. [PMID: 33012209 DOI: 10.2217/imt-2020-0007] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
180 Li A, Yi M, Qin S, Song Y, Chu Q, Wu K. Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy. J Hematol Oncol 2019;12:35. [PMID: 30935414 DOI: 10.1186/s13045-019-0721-x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 22.3] [Reference Citation Analysis]
181 Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, Lordick F, Kim SB, Tajika M, Lockhart AC, Arkenau HT, El-Hajbi F, Gupta M, Pfeiffer P, Bhagia P, Cao ZA, Lunceford J, Suryawanshi S, Ayers M, J Marton M, Kato K. T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer. Future Oncol 2022. [PMID: 35852104 DOI: 10.2217/fon-2021-1134] [Reference Citation Analysis]
182 Song P, Li W, Wu X, Qian Z, Ying J, Gao S, He J. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma. Cancer Immunol Immunother 2022. [PMID: 35152302 DOI: 10.1007/s00262-022-03143-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
183 Yaseen MM, Abuharfeil NM, Darmani H. The clinical and prognostic significance of CMTM6/PD-L1 in oncology. Clin Transl Oncol 2022. [PMID: 35278198 DOI: 10.1007/s12094-022-02811-0] [Reference Citation Analysis]
184 Huang XZ, Gao P, Song YX, Xu Y, Sun JX, Chen XW, Zhao JH, Wang ZN. Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients. Oncoimmunology 2019;8:e1665973. [PMID: 31741763 DOI: 10.1080/2162402X.2019.1665973] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 11.3] [Reference Citation Analysis]
185 Ye F, Liang Y, Hu J, Hu Y, Liu Y, Cheng Z, Ou Y, Xu C, Jiang H. DNA Methylation Modification Map to Predict Tumor Molecular Subtypes and Efficacy of Immunotherapy in Bladder Cancer. Front Cell Dev Biol 2021;9:760369. [PMID: 34926451 DOI: 10.3389/fcell.2021.760369] [Reference Citation Analysis]
186 Zhang X, Liu Q, Liao Q, Zhao Y. Pancreatic Cancer, Gut Microbiota, and Therapeutic Efficacy. J Cancer. 2020;11:2749-2758. [PMID: 32226493 DOI: 10.7150/jca.37445] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
187 Hage C, Hoves S, Ashoff M, Schandl V, Hört S, Rieder N, Heichinger C, Berrera M, Ries CH, Kiessling F, Pöschinger T. Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy. PLoS One 2019;14:e0219517. [PMID: 31291357 DOI: 10.1371/journal.pone.0219517] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
188 Chen L, Zhao R, Sun H, Huang R, Pan H, Zuo Y, Zhang L, Xue Y, Li X, Song H. The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors. Front Pharmacol 2022;13:833584. [DOI: 10.3389/fphar.2022.833584] [Reference Citation Analysis]
189 Zhang T, Zheng S, Liu Y, Li X, Wu J, Sun Y, Liu G. DNA damage response and PD-1/PD-L1 pathway in ovarian cancer. DNA Repair (Amst) 2021;102:103112. [PMID: 33838550 DOI: 10.1016/j.dnarep.2021.103112] [Reference Citation Analysis]
190 Xu H, Lyu X, Yi M, Zhao W, Song Y, Wu K. Organoid technology and applications in cancer research. J Hematol Oncol 2018;11:116. [PMID: 30219074 DOI: 10.1186/s13045-018-0662-9] [Cited by in Crossref: 76] [Cited by in F6Publishing: 83] [Article Influence: 19.0] [Reference Citation Analysis]
191 Inoue S, Horiuchi Y, Setoyama Y, Takeuchi Y, Beck Y, Murakami T, Odaka A. Immune Checkpoint Inhibition Followed by Tumor Infiltration of Dendritic Cells in Murine Neuro-2a Neuroblastoma. J Surg Res 2020;253:201-13. [PMID: 32380346 DOI: 10.1016/j.jss.2020.03.059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
192 Lu J, Ding J, Liu Z, Chen T. Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review). Int J Oncol 2022;60:12. [PMID: 34981814 DOI: 10.3892/ijo.2022.5302] [Reference Citation Analysis]
193 Zhang ZC, Guo JN, Zhang N, Wang ZQ, Lou G, Cui BB, Yang C. Identification and Validation of Immune-Related Gene for Predicting Prognosis and Therapeutic Response in Ovarian Cancer. Front Immunol 2021;12:763791. [PMID: 34880862 DOI: 10.3389/fimmu.2021.763791] [Reference Citation Analysis]
194 Wang Q, Li M, Yang M, Yang Y, Song F, Zhang W, Li X, Chen K. Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy. Aging (Albany NY) 2020;12:3312-39. [PMID: 32091408 DOI: 10.18632/aging.102814] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
195 Chen C, Zhang W, Zhou D, Zhang Y. Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review. Front Oncol 2021;11:757403. [PMID: 34820328 DOI: 10.3389/fonc.2021.757403] [Reference Citation Analysis]
196 Liu C, Liao J, Wu X, Zhao X, Sun S, Wang H, Hu Z, Zhang Y, Yu H, Wang J. A phase II study of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer. Thorac Cancer 2022. [PMID: 35388976 DOI: 10.1111/1759-7714.14414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
197 Katongole P, Sande OJ, Reynolds SJ, Joloba M, Kajumbula H, Kalungi S, Ssebambulidde K, Nakimuli C, Atuheirwe M, Orem J, Niyonzima N. Soluble Programmed Death-Ligand 1 (sPD-L1) is Elevated in Aggressive Prostate Cancer Disease Among African Men. Oncol Ther 2022. [PMID: 35128628 DOI: 10.1007/s40487-022-00184-6] [Reference Citation Analysis]
198 Yi H, Lin Y, Li Y, Guo Y, Yuan L, Mao Y, Zhan C. Pan-Cancer Analysis of B4GALNT1 as a Potential Prognostic and Immunological Biomarker. Journal of Immunology Research 2022;2022:1-28. [DOI: 10.1155/2022/4355890] [Reference Citation Analysis]
199 Hudson K, Cross N, Jordan-Mahy N, Leyland R. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. Front Immunol. 2020;11:568931. [PMID: 33193345 DOI: 10.3389/fimmu.2020.568931] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
200 Lin W, Liu J, Chen J, Li J, Qiu S, Ma J, Lin X, Zhang L, Wu J. Peptides of tetraspanin oncoprotein CD151 trigger active immunity against primary tumour and experimental lung metastasis. EBioMedicine 2019;49:133-44. [PMID: 31668880 DOI: 10.1016/j.ebiom.2019.10.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
201 Hashemi S, Fransen MF, Niemeijer A, Ben Taleb N, Houda I, Veltman J, Becker-Commissaris A, Daniels H, Crombag L, Radonic T, Jongeneel G, Tarasevych S, Looysen E, van Laren M, Tiemessen M, van Diepen V, Maassen-van den Brink K, Thunnissen E, Bahce I. Surprising impact of stromal TIL's on immunotherapy efficacy in a real-world lung cancer study. Lung Cancer 2021;153:81-9. [PMID: 33465698 DOI: 10.1016/j.lungcan.2021.01.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
202 Jia H, Guo J, Liu Z, Chen P, Li Y, Li R, Yang Y, Li X, Wei P, Zhong J, Ren F, Wang M, Ren J, Feng Z, Zhao T. High expression of CD28 enhanced the anti-cancer effect of siRNA-PD-1 through prompting the immune response of melanoma-bearing mice. International Immunopharmacology 2022;105:108572. [DOI: 10.1016/j.intimp.2022.108572] [Reference Citation Analysis]
203 Zheng Y, Tang L, Liu Z. Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer. BMC Cancer 2021;21:1322. [PMID: 34893051 DOI: 10.1186/s12885-021-09044-4] [Reference Citation Analysis]
204 Su F, Song Q, Zhang C, Xu X, Li M, Yao D, Wu L, Qu X, Guan H, Yu G, Yang J, Zhao C. A β-1,3/1,6-glucan from Durvillaea Antarctica inhibits tumor progression in vivo as an immune stimulator. Carbohydrate Polymers 2019;222:114993. [DOI: 10.1016/j.carbpol.2019.114993] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
205 Li T, Liu T, Zhu W, Xie S, Zhao Z, Feng B, Guo H, Yang R. Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects. Clin Med Insights Oncol 2021;15:11795549211035540. [PMID: 34408525 DOI: 10.1177/11795549211035540] [Reference Citation Analysis]
206 Kang YB, Cai Y. Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer. World J Gastroenterol 2021;27:5362-75. [PMID: 34539138 DOI: 10.3748/wjg.v27.i32.5362] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
207 Ushio R, Hiroi M, Matsumoto A, Mori K, Yamamoto N, Ohmori Y. Enhanced Cytotoxic Effects in Human Oral Squamous Cell Carcinoma Cells Treated with Combined Methyltransferase Inhibitors and Histone Deacetylase Inhibitors. Biomedicines 2022;10:763. [DOI: 10.3390/biomedicines10040763] [Reference Citation Analysis]
208 Cai D, Li J, Liu D, Hong S, Qiao Q, Sun Q, Li P, Lyu N, Sun T, Xie S, Guo L, Ni L, Jin L, Dong C. Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy. Cell Mol Immunol 2020;17:227-36. [PMID: 31611650 DOI: 10.1038/s41423-019-0305-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
209 Zhao P, Li L, Jiang X, Li Q. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol 2019;12:54. [PMID: 31151482 DOI: 10.1186/s13045-019-0738-1] [Cited by in Crossref: 118] [Cited by in F6Publishing: 113] [Article Influence: 39.3] [Reference Citation Analysis]
210 Aghajani MJ, Roberts TL, Yang T, McCafferty CE, Caixeiro NJ, DeSouza P, Niles N. Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer. Endocr Connect 2019;8:1040-51. [PMID: 31252406 DOI: 10.1530/EC-19-0210] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
211 Rocha ML, Schmid KW, Czapiewski P. The prevalence of DNA microsatellite instability in anaplastic thyroid carcinoma - systematic review and discussion of current therapeutic options. Contemp Oncol (Pozn) 2021;25:213-23. [PMID: 34729042 DOI: 10.5114/wo.2021.110052] [Reference Citation Analysis]
212 Niu M, Liu Y, Yi M, Jiao D, Wu K. Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer. Front Immunol 2022;13:827921. [DOI: 10.3389/fimmu.2022.827921] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
213 Sun H, Yu T, Li X, Lei Y, Li J, Wang X, Peng P, Ni D, Wang X, Luo Y. Second near-infrared photothermal-amplified immunotherapy using photoactivatable composite nanostimulators. J Nanobiotechnology 2021;19:433. [PMID: 34930269 DOI: 10.1186/s12951-021-01197-5] [Reference Citation Analysis]
214 Chen B, Yang M, Li K, Li J, Xu L, Xu F, Xu Y, Ren D, Zhang J, Liu L. Immune-related genes and gene sets for predicting the response to anti-programmed death 1 therapy in patients with primary or metastatic non-small cell lung cancer. Oncol Lett 2021;22:540. [PMID: 34084219 DOI: 10.3892/ol.2021.12801] [Reference Citation Analysis]
215 Fernandes MGO, Cruz-martins N, Machado JC, Costa JL, Hespanhol V. The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management. Cancer Cell Int 2021;21. [DOI: 10.1186/s12935-021-02382-0] [Reference Citation Analysis]
216 Zouein J, Kesrouani C, Kourie HR. PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare. Immunotherapy 2021;13:1053-65. [PMID: 34190579 DOI: 10.2217/imt-2020-0336] [Reference Citation Analysis]
217 Tang X, Sui X, Weng L, Liu Y. SNAIL1: Linking Tumor Metastasis to Immune Evasion. Front Immunol 2021;12:724200. [PMID: 34917071 DOI: 10.3389/fimmu.2021.724200] [Reference Citation Analysis]
218 Gao H, Wu Y, Shi J, Zhang X, Liu T, Hu B, Jia B, Wan Y, Liu Z, Wang F. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy. J Immunother Cancer 2020;8:e001156. [PMID: 33203663 DOI: 10.1136/jitc-2020-001156] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
219 Li A, Yi M, Qin S, Chu Q, Luo S, Wu K. Prospects for combining immune checkpoint blockade with PARP inhibition. J Hematol Oncol 2019;12:98. [PMID: 31521196 DOI: 10.1186/s13045-019-0784-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 14.3] [Reference Citation Analysis]
220 Yu X, Gao R, Li Y, Zeng C. Regulation of PD-1 in T cells for cancer immunotherapy. Eur J Pharmacol 2020;881:173240. [PMID: 32497624 DOI: 10.1016/j.ejphar.2020.173240] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
221 Bao Y, Wen L, Chen W, Zhao J, Yang Y, Wei T, Zhang J, Liang T. Case report: A case of heterogeneity of the antitumor response to immune checkpoint inhibitors in a patient with relapsed hepatocellular carcinoma. Front Oncol 2022;12:899811. [DOI: 10.3389/fonc.2022.899811] [Reference Citation Analysis]
222 Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, Zeng WJ, Liu Z, Cheng Q. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res 2021;40:184. [PMID: 34088360 DOI: 10.1186/s13046-021-01987-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
223 Wu Q, Liu J, Wu S, Xie X. The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: A study based on 44 cohorts. Int Immunopharmacol 2021;92:107303. [PMID: 33465728 DOI: 10.1016/j.intimp.2020.107303] [Reference Citation Analysis]
224 Rubins DJ, Meng X, McQuade P, Klimas M, Getty K, Lin SA, Connolly BM, O'Malley SS, Haley H, Purcell M, Gantert L, Holahan M, Lindgren J, Eklund P, Ekblad C, Frejd FY, Hostetler ED, González Trotter DE, Evelhoch JL. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1. Mol Imaging Biol 2021;23:241-9. [PMID: 33098025 DOI: 10.1007/s11307-020-01544-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
225 Guo X, Shen W. Latest evidence on immunotherapy for cholangiocarcinoma.Oncol Lett. 2020;20:381. [PMID: 33154779 DOI: 10.3892/ol.2020.12244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
226 Ma YS, Wang XF, Zhang YJ, Luo P, Long HD, Li L, Yang HQ, Xie RT, Jia CY, Lu GX, Chang ZY, Zhang JJ, Xue SB, Lv ZW, Yu F, Xia Q, Fu D. Inhibition of USP14 Deubiquitinating Activity as a Potential Therapy for Tumors with p53 Deficiency. Mol Ther Oncolytics 2020;16:147-57. [PMID: 32055678 DOI: 10.1016/j.omto.2019.12.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
227 Xu D, Li J, Wang D, Zhou L, Jin J, Wang Y. Prediction performance of twelve tumor mutation burden panels in melanoma and non-small cell lung cancer. Crit Rev Oncol Hematol 2021;169:103573. [PMID: 34933103 DOI: 10.1016/j.critrevonc.2021.103573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 Yi M, Niu M, Zhang J, Li S, Zhu S, Yan Y, Li N, Zhou P, Chu Q, Wu K. Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers. J Hematol Oncol 2021;14:146. [PMID: 34526097 DOI: 10.1186/s13045-021-01155-6] [Reference Citation Analysis]
229 Hosseinkhani N, Derakhshani A, Shadbad MA, Argentiero A, Racanelli V, Kazemi T, Mokhtarzadeh A, Brunetti O, Silvestris N, Baradaran B. The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead. Front Immunol 2021;12:676181. [PMID: 34093577 DOI: 10.3389/fimmu.2021.676181] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
230 Liang J, Chen D, Chen L, She X, Zhang H, Xiao Y. The potentiality of immunotherapy for sarcomas: a summary of potential predictive biomarkers. Future Oncol 2020;16:1211-23. [PMID: 32396026 DOI: 10.2217/fon-2020-0118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
231 Shang J, Han X, Zha H, Tao H, Li X, Yuan F, Chen G, Wang L, Ma J, Hu Y. Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade. Front Oncol 2021;11:585271. [PMID: 33718140 DOI: 10.3389/fonc.2021.585271] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
232 Li Q, Zhou ZW, Lu J, Luo H, Wang SN, Peng Y, Deng MS, Song GB, Wang JM, Wei X, Wang D, Westover KD, Xu CX. PD-L1P146R is prognostic and a negative predictor of response to immunotherapy in gastric cancer. Mol Ther 2021:S1525-0016(21)00468-8. [PMID: 34547468 DOI: 10.1016/j.ymthe.2021.09.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
233 Nie W, Gan L, Wang X, Gu K, Qian FF, Hu MJ, Zhang D, Chen SQ, Lu J, Cao SH, Li JW, Wang Y, Zhang B, Wang SY, Li CH, Yang P, Xu MD, Zhang XY, Zhong H, Han BH. Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation. Oncoimmunology 2021;10:1865670. [PMID: 33537171 DOI: 10.1080/2162402X.2020.1865670] [Reference Citation Analysis]
234 Oliveira RC, Tavares-silva E, Abrantes AM, Antunes H, Teixeira P, Gomes A, Martins R, Furtado E, Figueiredo A, Costa B, Cipriano MA, Tralhão JG, Botelho MF. De novo colorectal cancer after liver and kidney transplantation–Microenvironment disturbance. Transplantation Reports 2020;5:100057. [DOI: 10.1016/j.tpr.2020.100057] [Reference Citation Analysis]
235 Vuky J, Balar AV, Castellano D, O'Donnell PH, Grivas P, Bellmunt J, Powles T, Bajorin D, Hahn NM, Savage MJ, Fang X, Godwin JL, Frenkl TL, Homet Moreno B, de Wit R, Plimack ER. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol 2020;38:2658-66. [PMID: 32552471 DOI: 10.1200/JCO.19.01213] [Cited by in Crossref: 46] [Cited by in F6Publishing: 22] [Article Influence: 23.0] [Reference Citation Analysis]
236 Tian T, Wang J, Yin F, Wu M, He W, Wang X, Zha Z, Wang H. Activation of Cascade-Like Antitumor Immune Responses through In Situ Doxorubicin Stimulation and Blockade of Checkpoint Coinhibitory Receptor TIGIT. Adv Healthc Mater 2022;11:e2102080. [PMID: 34655464 DOI: 10.1002/adhm.202102080] [Reference Citation Analysis]
237 Niu M, Yi M, Li N, Wu K, Wu K. Advances of Targeted Therapy for Hepatocellular Carcinoma. Front Oncol 2021;11:719896. [PMID: 34381735 DOI: 10.3389/fonc.2021.719896] [Reference Citation Analysis]
238 Yi M, Jiao D, Qin S, Chu Q, Li A, Wu K. Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy. Integr Cancer Ther 2019;18:1534735419876351. [PMID: 31517538 DOI: 10.1177/1534735419876351] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
239 Wu TM, Liu JB, Liu Y, Shi Y, Li W, Wang GR, Ma YS, Fu D. Power and Promise of Next-Generation Sequencing in Liquid Biopsies and Cancer Control. Cancer Control 2020;27:1073274820934805. [PMID: 32806937 DOI: 10.1177/1073274820934805] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
240 Riedesser JE, Ebert MP, Betge J. Precision medicine for metastatic colorectal cancer in clinical practice. Ther Adv Med Oncol 2022;14:175883592110727. [DOI: 10.1177/17588359211072703] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
241 Siewe N, Friedman A. TGF-β inhibition can overcome cancer primary resistance to PD-1 blockade: A mathematical model. PLoS One 2021;16:e0252620. [PMID: 34061898 DOI: 10.1371/journal.pone.0252620] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
242 Decazes P, Bohn P. Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future Applications. Cancers (Basel) 2020;12:E371. [PMID: 32041105 DOI: 10.3390/cancers12020371] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
243 Sagredou S, Dalezis P, Papadopoulou E, Voura M, Deligiorgi MV, Nikolaou M, Panayiotidis MI, Nasioulas G, Sarli V, Trafalis DT. Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden. Pharmaceutics 2021;13:885. [PMID: 34203761 DOI: 10.3390/pharmaceutics13060885] [Reference Citation Analysis]
244 Choi MG, Kim YJ, Lee JC, Rho JK, Choi CM. Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in non-small cell lung cancer. Thorac Cancer 2020;11:3337-45. [PMID: 33017518 DOI: 10.1111/1759-7714.13677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
245 Morsch R, Rose M, Maurer A, Cassataro MA, Braunschweig T, Knüchel R, Vögeli TA, Ecke T, Eckstein M, Weyerer V, Esposito I, Ackermann M, Niegisch G, Gaisa NT; German Study Group of Bladder Cancer (DFBK e.V.). Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation. BMC Cancer 2020;20:230. [PMID: 32188412 DOI: 10.1186/s12885-020-06727-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
246 Wu Y, Xu J, Du C, Wu Y, Xia D, Lv W, Hu J. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis. Front Oncol 2019;9:1161. [PMID: 31750249 DOI: 10.3389/fonc.2019.01161] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 14.7] [Reference Citation Analysis]
247 Yan S, Zeng H, Jin K, Shao F, Liu Z, Chang Y, Wang Y, Zhu Y, Wang Z, Xu L, Xu J. NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer. J Immunother Cancer 2022;10:e004569. [PMID: 35523436 DOI: 10.1136/jitc-2022-004569] [Reference Citation Analysis]
248 Zhao L, Liu C, Xie G, Wu F, Hu C. Multiple Primary Lung Cancers: A New Challenge in the Era of Precision Medicine. Cancer Manag Res 2020;12:10361-74. [PMID: 33116891 DOI: 10.2147/CMAR.S268081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
249 Li X, Fu S, Huang Y, Luan T, Wang H, Wang J. Identification of a novel metabolism-related gene signature associated with the survival of bladder cancer. BMC Cancer 2021;21:1267. [PMID: 34819038 DOI: 10.1186/s12885-021-09006-w] [Reference Citation Analysis]
250 Agarwal Y, Milling LE, Chang JYH, Santollani L, Sheen A, Lutz EA, Tabet A, Stinson J, Ni K, Rodrigues KA, Moyer TJ, Melo MB, Irvine DJ, Wittrup KD. Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity. Nat Biomed Eng 2022. [PMID: 35013574 DOI: 10.1038/s41551-021-00831-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
251 Yi M, Dong B, Qin S, Chu Q, Wu K, Luo S. Advances and perspectives of PARP inhibitors. Exp Hematol Oncol 2019;8:29. [PMID: 31737426 DOI: 10.1186/s40164-019-0154-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]
252 Wang J, Zhang R, Lin Z, Zhang S, Chen Y, Tang J, Hong J, Zhou X, Zong Y, Xu Y, Meng R, Xu S, Liu L, Zhang T, Yang K, Dong X, Wu G. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer. J Hematol Oncol 2020;13:99. [PMID: 32690037 DOI: 10.1186/s13045-020-00926-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
253 Zhu Z, Huang J, Li X, Xing J, Chen Q, Liu R, Hua F, Qiu Z, Song Y, Bai C, Mo YY, Zhang Z. Gut microbiota regulate tumor metastasis via circRNA/miRNA networks. Gut Microbes. 2020;12:1788891. [PMID: 32686598 DOI: 10.1080/19490976.2020.1788891] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 12.0] [Reference Citation Analysis]
254 Hodkinson BP, Schaffer M, Brody JD, Jurczak W, Carpio C, Ben-Yehuda D, Avivi I, Forslund A, Özcan M, Alvarez J, Ceulemans R, Fourneau N, Younes A, Balasubramanian S. Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation. Transl Oncol 2021;14:100977. [PMID: 33395752 DOI: 10.1016/j.tranon.2020.100977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
255 Wu L, Quan W, Luo Q, Pan Y, Peng D, Zhang G. Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma. Front Mol Biosci 2020;7:567950. [PMID: 33195412 DOI: 10.3389/fmolb.2020.567950] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
256 Summers RM. Imaging Biomarkers to Assess Response to Immune Checkpoint Inhibitors in Solid Tumors to Tailor Therapy. Radiology 2021;299:120-1. [PMID: 33502277 DOI: 10.1148/radiol.2021204407] [Reference Citation Analysis]
257 Sun Y, Jiang L, Wen T, Guo X, Shao X, Qu H, Chen X, Song Y, Wang F, Qu X, Li Z. Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study. Front Pharmacol 2021;12:670900. [PMID: 34489691 DOI: 10.3389/fphar.2021.670900] [Reference Citation Analysis]
258 Ma X, Zhang Y, Wang S, Yu J. Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immunocheckpoint inhibitors for non-small cell lung cancer (NSCLC). J Cancer 2021;12:584-94. [PMID: 33391454 DOI: 10.7150/jca.48105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
259 Li F, Li C, Cai X, Xie Z, Zhou L, Cheng B, Zhong R, Xiong S, Li J, Chen Z, Yu Z, He J, Liang W. The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis. EClinicalMedicine 2021;41:101134. [PMID: 34585125 DOI: 10.1016/j.eclinm.2021.101134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
260 Fang Y, Wang L, Wan C, Sun Y, Van der Jeught K, Zhou Z, Dong T, So KM, Yu T, Li Y, Eyvani H, Colter AB, Dong E, Cao S, Wang J, Schneider BP, Sandusky GE, Liu Y, Zhang C, Lu X, Zhang X. MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation. J Clin Invest 2021;131:140837. [PMID: 32990678 DOI: 10.1172/JCI140837] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
261 Rizzo A, Mollica V, Santoni M, Rosellini M, Marchetti A, Ricci AD, Grilli G, Greco A, Montironi R, Ardizzoni A, Massari F. Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis. Immunotherapy 2021;13:783-93. [PMID: 33906376 DOI: 10.2217/imt-2021-0005] [Reference Citation Analysis]
262 Simmons CE, Brezden-Masley C, McCarthy J, McLeod D, Joy AA. Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer. Ther Adv Med Oncol 2020;12:1758835920909091. [PMID: 33014143 DOI: 10.1177/1758835920909091] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
263 Janka EA, Várvölgyi T, Sipos Z, Soós A, Hegyi P, Kiss S, Dembrovszky F, Csupor D, Kéringer P, Pécsi D, Solymár M, Emri G. Predictive Performance of Serum S100B Versus LDH in Melanoma Patients: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:772165. [PMID: 34950582 DOI: 10.3389/fonc.2021.772165] [Reference Citation Analysis]
264 Shimada Y, Okuda S, Watanabe Y, Tajima Y, Nagahashi M, Ichikawa H, Nakano M, Sakata J, Takii Y, Kawasaki T, Homma KI, Kamori T, Oki E, Ling Y, Takeuchi S, Wakai T. Histopathological characteristics and artificial intelligence for predicting tumor mutational burden-high colorectal cancer. J Gastroenterol 2021;56:547-59. [PMID: 33909150 DOI: 10.1007/s00535-021-01789-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
265 Lenz JA, Assenmacher CA, Costa V, Louka K, Rau S, Keuler NS, Zhang PJ, Maki RG, Durham AC, Radaelli E, Atherton MJ. Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma. Cancer Immunol Immunother 2021. [PMID: 34415404 DOI: 10.1007/s00262-021-03033-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
266 Liao G, Qian Y, Arooj S, Zhao Z, Yan M, Li Z, Yang H, Zheng T, Li G, Li X, Khan M. Radiation Plus Anti-PD-1 Therapy for NSCLC Brain Metastases: A Retrospective Study. Front Oncol 2021;11:742971. [PMID: 34745964 DOI: 10.3389/fonc.2021.742971] [Reference Citation Analysis]
267 Miao L, Qi J, Zhao Q, Wu QN, Wei DL, Wei XL, Liu J, Chen J, Zeng ZL, Ju HQ, Luo HY, Xu RH. Targeting the STING pathway in tumor-associated macrophages regulates innate immune sensing of gastric cancer cells. Theranostics 2020;10:498-515. [PMID: 31903134 DOI: 10.7150/thno.37745] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 12.0] [Reference Citation Analysis]
268 Tinsley N, Zhou C, Tan G, Rack S, Lorigan P, Blackhall F, Krebs M, Carter L, Thistlethwaite F, Graham D, Cook N. Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer. Oncologist 2020;25:55-63. [PMID: 31292268 DOI: 10.1634/theoncologist.2019-0160] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 15.7] [Reference Citation Analysis]
269 Moore TV, Scurti GM, DeJong M, Wang SY, Dalheim AV, Wagner CR, Hutchens KA, Speiser JJ, Godellas CV, Fountain C, Fleser J, Moudgil T, Thomas M, Murray D, Curti BD, Clark JI, Fox BA, Nishimura MI. HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells. Mol Ther Oncolytics 2021;20:352-63. [PMID: 33614916 DOI: 10.1016/j.omto.2021.01.014] [Reference Citation Analysis]
270 Lei Y, Li X, Huang Q, Zheng X, Liu M. Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade. Front Oncol 2021;11:617335. [PMID: 33777757 DOI: 10.3389/fonc.2021.617335] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
271 Huang J, Kang W, Pan S, Yu C, Jie Z, Chen C, Ciccarone F. NOL12 as an Oncogenic Biomarker Promotes Hepatocellular Carcinoma Growth and Metastasis. Oxidative Medicine and Cellular Longevity 2022;2022:1-17. [DOI: 10.1155/2022/6891155] [Reference Citation Analysis]
272 Shi J, Liu J, Tu X, Li B, Tong Z, Wang T, Zheng Y, Shi H, Zeng X, Chen W, Yin W, Fang W. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy. J Immunother Cancer 2022;10:e003133. [PMID: 35101942 DOI: 10.1136/jitc-2021-003133] [Reference Citation Analysis]
273 Ding R, Liu S, Wang S, Chen H, Wang F, Xu Q, Zhu L, Dong X, Gu Y, Zhang X, Chao CC, Gao Q. Single-cell transcriptome analysis of the heterogeneous effects of differential expression of tumor PD-L1 on responding TCR-T cells. Theranostics 2021;11:4957-74. [PMID: 33754038 DOI: 10.7150/thno.55075] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
274 Yi M, Zhang J, Li A, Niu M, Yan Y, Jiao Y, Luo S, Zhou P, Wu K. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1. J Hematol Oncol 2021;14:27. [PMID: 33593403 DOI: 10.1186/s13045-021-01045-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
275 Zelin E, Maronese CA, Dri A, Toffoli L, Di Meo N, Nazzaro G, Zalaudek I. Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response. J Clin Med 2022;11:3364. [PMID: 35743435 DOI: 10.3390/jcm11123364] [Reference Citation Analysis]
276 Guo Y, Xie Y, Luo Y. The Role of Long Non-Coding RNAs in the Tumor Immune Microenvironment. Front Immunol 2022;13:851004. [PMID: 35222443 DOI: 10.3389/fimmu.2022.851004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
277 Zou Q, Lei X, Xu A, Li Z, He Q, Huang X, Xu G, Tian F, Ding Y, Zhu W. Chemokines in progression, chemoresistance, diagnosis, and prognosis of colorectal cancer. Front Immunol 2022;13:724139. [DOI: 10.3389/fimmu.2022.724139] [Reference Citation Analysis]
278 Cho YH, Choi MG, Kim DH, Choi YJ, Kim SY, Sung KJ, Lee JC, Kim SY, Rho JK, Choi CM. Natural Killer Cells as a Potential Biomarker for Predicting Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer. Target Oncol 2020;15:241-7. [PMID: 32285316 DOI: 10.1007/s11523-020-00712-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
279 Maestri M, Pallozzi M, Santopaolo F, Cerrito L, Pompili M, Gasbarrini A, Ponziani FR. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2033208] [Reference Citation Analysis]
280 Nielsen MA, Juul-madsen K, Stegmayr J, Gao C, Mehta AY, Greisen SR, Kragstrup TW, Hvid M, Vorup-jensen T, Cummings RD, Leffler H, Deleuran BW. Galectin-3 Decreases 4-1BBL Bioactivity by Crosslinking Soluble and Membrane Expressed 4-1BB. Front Immunol 2022;13:915890. [DOI: 10.3389/fimmu.2022.915890] [Reference Citation Analysis]
281 Miracco C, Toti P, Gelmi MC, Aversa S, Baldino G, Galluzzi P, De Francesco S, Petrelli F, Sorrentino E, Belmonte G, Galimberti D, Bracco S, Hadjistilianou T. Retinoblastoma Is Characterized by a Cold, CD8+ Cell Poor, PD-L1- Microenvironment, Which Turns Into Hot, CD8+ Cell Rich, PD-L1+ After Chemotherapy. Invest Ophthalmol Vis Sci 2021;62:6. [PMID: 33538768 DOI: 10.1167/iovs.62.2.6] [Reference Citation Analysis]
282 Lingling Z, Jiewei L, Li W, Danli Y, Jie Z, Wen L, Dan P, Lei P, Qinghua Z. Molecular regulatory network of PD-1/PD-L1 in non-small cell lung cancer. Pathology - Research and Practice 2020;216:152852. [DOI: 10.1016/j.prp.2020.152852] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
283 Yuan X, Yi M, Zhang W, Xu L, Chu Q, Luo S, Wu K. The biology of combination immunotherapy in recurrent metastatic head and neck cancer. Int J Biochem Cell Biol 2021;136:106002. [PMID: 33962022 DOI: 10.1016/j.biocel.2021.106002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
284 Noh BJ, Kwak JY, Eom DW. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma. BMC Cancer 2020;20:58. [PMID: 31992245 DOI: 10.1186/s12885-020-6553-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
285 Yan X, Zhou Q, Zhu H, Liu W, Xu H, Yin W, Zhao M, Jiang X, Ren C. The clinical features, prognostic significance, and immune heterogeneity of CD37 in diffuse gliomas. iScience 2021;24:103249. [PMID: 34755091 DOI: 10.1016/j.isci.2021.103249] [Reference Citation Analysis]
286 Shi L, Sheng J, Chen G, Zhu P, Shi C, Li B, Park C, Wang J, Zhang B, Liu Z, Yang X. Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance. J Immunother Cancer 2020;8:e000973. [PMID: 33028692 DOI: 10.1136/jitc-2020-000973] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
287 Li W, Yu H. Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases. J Cancer Res Clin Oncol 2020;146:137-52. [PMID: 31813004 DOI: 10.1007/s00432-019-03094-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
288 Zang B, Chen C, Zhao JQ. PD-1 gene rs10204525 and rs7421861 polymorphisms are associated with increased risk and clinical features of esophageal cancer in a Chinese Han population. Aging (Albany NY) 2020;12:3771-90. [PMID: 32084010 DOI: 10.18632/aging.102845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
289 Urbina-Jara LK, Rojas-Martinez A, Martinez-Ledesma E, Aguilar D, Villarreal-Garza C, Ortiz-Lopez R. Landscape of Germline Mutations in DNA Repair Genes for Breast Cancer in Latin America: Opportunities for PARP-Like Inhibitors and Immunotherapy. Genes (Basel) 2019;10:E786. [PMID: 31658756 DOI: 10.3390/genes10100786] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
290 Setordzi P, Chang X, Liu Z, Wu Y, Zuo D. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy. Eur J Pharmacol 2021;895:173867. [PMID: 33460617 DOI: 10.1016/j.ejphar.2021.173867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]